Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $5.6 million, down from $7.7 million in 2024, primarily due to the timing of customer equipment purchases [13] - Gross margin improved to approximately 55%, up from 46% in 2024, reflecting lower cost of sales and a reduction in inventory reserves [13] - Total operating expenses decreased by approximately 10% to $6.9 million from 2024 [14] - The net loss was $3.7 million or $0.19 per share, an improvement from a net loss of $4.5 million or $0.22 per share in 2024 [14] Business Line Data and Key Metrics Changes - The backlog of orders for support services increased by 16%, and BIT Solution orders rose by 24% in Q1 2026 compared to the same period last year, indicating a growing recurring revenue trajectory [9][16] - The SteraMist Integrated System achieved its first commercial installation at a leading CDMO in June 2025, with four fully operational SIS enclosure installations by year-end [4][5] Market Data and Key Metrics Changes - The global ethylene oxide market was valued at $5.29 billion last year, with rising demand for sterilized medical consumables and improved healthcare infrastructure driving growth [10] - The company is actively pursuing opportunities in the food safety sector, with significant partners like Danone and Nestlé, following the FDA's approval of hydrogen peroxide as a direct food additive [7][8] Company Strategy and Development Direction - The company is focusing on execution and converting its pipeline into recognized revenue while advancing its technology platform [10] - A shift towards a recurring revenue model is emphasized, moving from episodic revenue to embedded revenue, which is expected to enhance customer dependency and long-term growth [31][32] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging year in 2025 due to factors like tariffs and political uncertainty but expressed optimism about future revenue growth, projecting around $12 million for 2026 [25][29] - The company is seeing signs of improvement as customers who deferred capital expenditures are beginning to move forward with projects [56] Other Important Information - The company received approvals from the HSE and BPR submissions, enhancing its market presence in the UK and the Netherlands [9] - The company is preparing to introduce its IHP device to the U.S. market through the FDA 510(k) pre-market notification process [10] Q&A Session Summary Question: Insight into global opportunities mentioned in the quarter - Management expects many EU states to follow suit with registrations, leveraging existing relationships and distributors [40] Question: Thoughts on operating expenses going forward - Operating expenses are expected to grow as a percentage of revenue but not significantly, indicating leverage in cost management [42] Question: Signs of improvement in customer capital expenditure projects - Management confirmed that customers are beginning to move forward with deferred projects [56] Question: Details on BIT Solution revenues for 2025 versus 2024 - There was an increase in BIT Solution usage, with customers moving towards auto shipment and advanced orders [58][60] Question: Potential applications for SteraMist in military settings - Management acknowledged the potential and expressed interest in exploring opportunities with military applications [71][75]

Core Viewpoint - The company has successfully entered the Sam's Club retail channel and launched customized products, which is expected to enhance brand image and product value [1] Group 1: Business Development - The related business is currently in its early development stage [1] - The company aims to seize channel opportunities actively [1] - The growth and effectiveness of the new channel will require some time to materialize [1] Group 2: Future Strategy - The company plans to deepen cooperation with leading retailers [1] - There is an intention to explore more customized and high-quality product lines [1] - The company will optimize its supply chain to meet the efficient turnover demands of the new channel [1]

Group 1 - JD's self-operated medical beauty clinics have made progress in channel expansion by launching on the Meituan app [1] - The first self-operated medical beauty clinic is named "JD Self-operated Beauty Dermatology (Yizhuang Store)" on Meituan [1] - This collaboration indicates potential channel cooperation between JD and Meituan despite their competitive landscape in food delivery services [1] Group 2 - JD's medical beauty clinic products are receiving subsidies from Meituan, with discounts of 50 yuan on various packages [1] - Some packages on Meituan are priced lower than on JD's own platform, such as the "磨皮水光肌套餐" priced at 948 yuan on Meituan compared to 998 yuan on JD [1] - This suggests that even a major player like JD relies on Meituan's strong local market presence for customer acquisition in the self-operated medical beauty sector [1]

Core Viewpoint - The collaboration between the founder of Pang Donglai and Jiu Gui Jiu has sparked significant market interest, leading to a notable increase in Jiu Gui Jiu's stock price despite a substantial decline in its financial performance [2][3]. Group 1: Stock Performance - Following the announcement of the collaboration, Jiu Gui Jiu's stock price rose by 18.73% by July 16, while no other liquor stocks exceeded a 10% increase during the same period [2]. - The best-performing liquor stock, Luzhou Laojiao, only saw a 6.98% increase in the same timeframe, highlighting Jiu Gui Jiu's exceptional market attention [2]. Group 2: Financial Performance - Jiu Gui Jiu's half-year earnings forecast revealed a projected revenue of only 560 million yuan, representing a year-on-year decline of 43% [2]. - The net profit is expected to be between 8 million and 12 million yuan, reflecting a staggering year-on-year drop of 90% to 93%, marking a ten-year low for the company [2]. Group 3: Industry Challenges - The significant decline in Jiu Gui Jiu's performance is attributed to multiple factors, including intense competition from major liquor brands, rapid channel expansion leading to high inventory levels, and a lag in brand marketing strategy compared to industry leaders [3]. - The current market environment is characterized by inventory reduction and price stabilization efforts, which have further pressured smaller liquor companies like Jiu Gui Jiu [3]. Group 4: Market Outlook - The market remains optimistic about the collaboration with Pang Donglai, primarily due to the success of the "Freedom Love" product previously launched with Baofeng Liquor, which achieved sales of 400 million yuan last year [3][4]. - Analysts believe that leveraging Pang Donglai's high customer traffic and brand influence could help Jiu Gui Jiu overcome its sales challenges, although long-term brand strength remains to be validated [4].